On the heels of a $278 million IPO, Forma Therapeutics is inching toward its first FDA filing. Its lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with acute myeloid leukemia ...
Credit: Getty Images. Olutasidenib is a small-molecule inhibitor of mutated IDH1. The Food and Drug Administration (FDA) has approved Rezlidhia™ (olutasidenib) for the treatment of adult patients with ...
The findings suggest that sequential mutant IDH inhibitor therapy might be one way to fight resistance in metastatic intrahepatic cholangiocarcinoma (IHCC). A new report is shedding light on how some ...
The approval was based on data from the double-blind, placebo-controlled ClarIDHy study. The Food and Drug Administration (FDA) has approved Tibsovo ® (ivosidenib) for the treatment of adult patients ...
Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study Twenty-one patients (escalation, n = 12; ...
Ivosidenib monotherapy is now approved by the FDA for patients with relapsed/refractory myelodysplastic syndrome with an IDH1 mutation. In conjunction with ivosidenib’s approval, the FDA also approved ...
A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers ...
A new article published in the journal Nature is reporting promising results from a landmark Phase 1 human trial testing a novel vaccine designed to help a patient's immune system better target brain ...
Voranigo and Temodar combination showed no serious side effects or dose-limiting toxicities in IDH1/2-mutant glioma patients. Treatment-emergent side effects led to dose reductions in 42.9% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results